Cornerstone Wealth Group LLC Boosts Holdings in Abbott Laboratories $ABT

Key Points

• Cornerstone Wealth Group increased its stake in Abbott by 40% in Q4, buying 27,471 shares to hold 96,096 shares valued at about $12.04 million, while institutional investors own roughly 75.18% of the stock.
• Company insiders have sold 3,055 shares over the past three months — including recent March 2 sales by EVP Daniel Gesua Sive Salvadori and VP John A. Jr. McCoy — leaving insiders with about 0.46% ownership.
• Analysts' consensus is a Moderate Buy with an average price target of $134.58; Abbott provided Q1 2026 EPS guidance of $1.120–$1.180 and FY 2026 guidance of $5.550–$5.800 and announced a $0.63 quarterly dividend (≈2.5% yield).

Cornerstone Wealth Group LLC lifted its stake in Abbott Laboratories (NYSE:ABT - Free Report) by 40.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,096 shares of the healthcare product maker's stock after purchasing an additional 27,471 shares during the period. Cornerstone Wealth Group LLC's holdings in Abbott Laboratories were worth $12,040,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Harbor Capital Advisors Inc. bought a new stake in Abbott Laboratories during the fourth quarter worth about $27,000. Cloud Capital Management LLC bought a new stake in Abbott Laboratories during the third quarter worth about $29,000. Guerra Advisors Inc bought a new stake in Abbott Laboratories during the third quarter worth about $31,000. Bridge Generations Wealth Management LLC bought a new stake in Abbott Laboratories during the third quarter worth about $33,000. Finally, Copia Wealth Management bought a new stake in Abbott Laboratories during the third quarter worth about $38,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares of the company's stock, valued at $2,846,504.24. This represents a 2.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 3,055 shares of company stock valued at $353,097. Company insiders own 0.46% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ABT shares. Weiss Ratings lowered shares of Abbott Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Monday, January 26th. BTIG Research dropped their price objective on shares of Abbott Laboratories from $140.00 to $131.00 and set a "buy" rating on the stock in a research note on Tuesday, March 31st. Leerink Partners dropped their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a "market perform" rating on the stock in a research note on Friday, January 30th. Sanford C. Bernstein dropped their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, January 23rd. Finally, Royal Bank Of Canada reduced their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an "outperform" rating for the company in a research note on Friday, January 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $134.58.

Abbott Laboratories Stock Up 0.5%

NYSE:ABT opened at $101.55 on Thursday. The firm has a market cap of $176.86 billion, a P/E ratio of 27.30, a P/E/G ratio of 1.61 and a beta of 0.79. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. Abbott Laboratories has a fifty-two week low of $99.05 and a fifty-two week high of $139.06. The firm has a 50-day simple moving average of $108.45 and a two-hundred day simple moving average of $119.18.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts' consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. Abbott Laboratories's revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.